NEW YORK (GenomeWeb) – Metamark Genetics said today that it has received Medicare coverage for ProMark, its proteomic test for prognosing early-stage prostate cancer.

Medicare Administrative Contractor Palmetto GBA issued a final local coverage decision for the test effective Oct. 10, 2016.

ProMark is a tool for identifying prostate cancer patients with likely non-aggressive forms of the disease that can be treated without surgery or radiation therapy. The test is intended for use in patients with biopsy Gleason Scores of 3+3 and 3+4.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.

Jun
19
Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.